Diagnostic Red Flags in Long COVID: Clinical Insights for Healthcare Professionals

Abstract

Long COVID, also known as post-acute sequelae of SARS-CoV-2 infection (PASC), presents a diagnostic challenge due to its heterogeneous manifestations and overlapping symptomatology with other conditions. Recognizing diagnostic red flags is critical for clinicians to distinguish long COVID from alternative diagnoses, identify potentially life-threatening complications, and optimize patient outcomes. This review article synthesizes current evidence on the epidemiology, pathophysiology, risk factors, clinical features, diagnostic approaches, management strategies, and evolving guideline recommendations with a focus on clinically significant red flags in the context of long COVID.

Introduction

The COVID-19 pandemic has left a considerable number of patients experiencing persistent symptoms beyond the acute phase, collectively termed as long COVID or PASC. These lingering symptoms can significantly impair quality of life and functional capacity. For healthcare professionals, the primary challenge is not only in recognizing the spectrum of post-acute symptoms but also in identifying red flags that may indicate serious underlying pathology or alternative diagnoses. Clinical acumen, supported by recent research and evolving guidelines, is essential in navigating the diagnostic complexities of long COVID.

Epidemiology / Disease Burden

Long COVID affects an estimated 10–30% of individuals following SARS-CoV-2 infection, with variability depending on study population and diagnostic criteria. Recent cohort studies highlight its prevalence across all age groups, including pediatric populations, but with higher incidence among adults, females, and those with severe acute disease. The disease burden extends beyond persistent fatigue and breathlessness, encompassing neuropsychiatric, cardiovascular, and multi-system manifestations that contribute to significant healthcare utilization, societal costs, and disability-adjusted life years (DALYs).

Pathophysiology

The mechanisms underlying long COVID are multifactorial and incompletely understood. Proposed mechanisms include persistent viral reservoirs, immune dysregulation with ongoing inflammation, autoimmunity, endothelial dysfunction, microvascular injury, and autonomic nervous system imbalance. These processes contribute to the heterogeneous clinical phenotype and are implicated in the emergence of red flags such as new-onset neurological deficits, thromboembolic events, and cardiac complications. Ongoing research is elucidating biomarkers and mechanistic pathways that may guide risk stratification and targeted interventions.

Risk Factors

Identifying individuals at higher risk for long COVID and its associated red flags is crucial for early intervention. Established risk factors include advanced age, female sex, higher BMI, pre-existing comorbidities (e.g., diabetes, cardiovascular disease, chronic lung disease), severity of acute COVID-19 illness, and the need for hospitalization or intensive care. Genetic predisposition and certain HLA haplotypes have also been implicated. Particular attention should be paid to immunosuppressed patients and those with prior organ dysfunction, as they may present atypically or develop severe complications.

Clinical Features

Long COVID is characterized by a constellation of symptoms lasting beyond 4–12 weeks post-infection, including fatigue, cognitive impairment (\"brain fog\"), dyspnea, chest pain, palpitations, anosmia, sleep disturbances, and myalgias. Diagnostic red flags warranting expedited evaluation include: unexplained hypoxemia, hemoptysis, new-onset arrhythmias, syncope, focal neurological deficits, severe chest pain, and evidence of deep vein thrombosis or pulmonary embolism. Neuropsychiatric red flags, such as acute psychosis, suicidal ideation, or rapid cognitive decline, indicate the need for urgent specialist referral. Clinicians must differentiate between symptoms attributable to long COVID and those signaling alternative diagnoses or superimposed pathology.

Diagnosis

Diagnosis of long COVID is primarily clinical, based on persistent or new symptoms following confirmed or probable SARS-CoV-2 infection, in the absence of alternative explanations. Comprehensive evaluation should include a detailed history, physical examination, and targeted investigations guided by red flag symptoms. Baseline tests may involve CBC, metabolic panel, inflammatory markers (CRP, ESR), D-dimer, cardiac biomarkers, chest imaging, and ECG. Additional workup, such as pulmonary function tests, echocardiography, neuroimaging, or autoimmune panels, is indicated if red flags are present. Diagnostic algorithms from recent guidelines emphasize ruling out serious complications (e.g., myocarditis, pulmonary embolism, cerebrovascular events) and secondary infections, particularly in immunocompromised hosts.

Treatment & Management

Management of long COVID is multidisciplinary and tailored to symptom severity, organ involvement, and the presence of red flags. Supportive care, symptom-directed therapy, and rehabilitation are mainstays for most patients. Pharmacological interventions may include analgesics, neuropathic pain agents, antidepressants, and, where indicated, anticoagulation or immunomodulatory therapies. Prompt recognition and management of red flags, such as acute coronary syndromes or thromboembolism, follow established emergency protocols. Coordination with cardiology, neurology, pulmonology, and mental health specialists is often required for complex cases. Patient education and shared decision-making are vital in setting realistic expectations and ensuring adherence to follow-up.

Recent Advances / Emerging Therapies

Recent advances in long COVID research have identified potential therapeutic targets, including antiviral agents, anti-inflammatory drugs, and interventions to restore autonomic balance. Clinical trials are underway exploring agents such as low-dose naltrexone, antihistamines, and monoclonal antibodies against inflammatory mediators. Digital health tools and telemedicine platforms facilitate symptom monitoring and early identification of red flags. Biomarker-driven approaches are promising for differentiating long COVID from overlapping syndromes and for risk stratification.

Guideline Recommendations

International and national guidelines, including those from NICE, CDC, and WHO, emphasize the importance of a holistic, patient-centered approach to long COVID. Red flags are highlighted as triggers for urgent referral and further investigation. Best practices include structured assessment pathways, multidisciplinary care teams, and regular re-evaluation. Guidelines advocate for individualized management plans, with escalation of care for patients exhibiting signs of organ dysfunction or rapid deterioration. Ongoing surveillance for emerging complications and inclusion in research registries are encouraged.

Conclusion

Long COVID represents a complex, evolving clinical entity with significant implications for patient care and public health. Vigilance for diagnostic red flags is essential to avoid missed diagnoses, prevent adverse outcomes, and allocate resources efficiently. As understanding of the pathophysiology and optimal management of long COVID continues to advance, clinicians must remain informed of the latest evidence and guideline recommendations to provide high-quality, evidence-based care to affected patients.